ReviewBiosensors2025
Actomyosin-Based Nanodevices for Sensing and Actuation: Bridging Biology and Bioengineering.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The actomyosin complex-nature's dynamic engine composed of actin filaments and myosin motors-is emerging as a versatile tool for bio-integrated nanotechnology. This review explores the growing potential of actomyosin-powered systems in biosensing and actuation applications, highlighting their compatibility with physiological conditions, responsiveness to biochemical and physical cues and modular adaptability. We begin with a comparative overview of natural and synthetic nanomachines, positioning actomyosin as a uniquely scalable and biocompatible platform. We then discuss experimental advances in controlling actomyosin activity through ATP, calcium, heat, light and electric fields, as well as their integration into in vitro motility assays, soft robotics and neural interface systems. Emphasis is placed on longstanding efforts to harness actomyosin as a biosensing element-capable of converting chemical or environmental signals into measurable mechanical or electrical outputs that can be used to provide valuable clinical and basic science information such as functional consequences of disease-associated genetic variants in cardiovascular genes. We also highlight engineering challenges such as stability, spatial control and upscaling, and examine speculative future directions, including emotion-responsive nanodevices. By bridging cell biology and bioengineering, actomyosin-based systems offer promising avenues for real-time sensing, diagnostics and therapeutic feedback in next-generation biosensors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.